Abstract: A liquid chromatography reagent kit includes a mobile phase anti-adsorption concentrate. The mobile phase anti-adsorption concentrate includes a first solvent, a buffer, an acid-base regulating reagent, and an anti-adsorption reagent. A ratio of a molarity of the buffer to a molarity of the acid-base regulating reagent is 400:1 to 1:1. A ratio of the molarity of the buffer to a molarity of the anti-adsorption reagent is 100:1 to 1:2.
Abstract: Kits and methods are provided for performing multiplex LAMP reactions. These kits and methods are directed to specific and sensitive methods of target nucleic acid detection and more specifically pathogen diagnostics such as detection of Coronavirus. The kits and methods utilize a plurality of sets of oligonucleotide primers for targeting the viral nucleic acid target.
Abstract: An analysis device includes a main control circuit, a sub-control circuit, a backup execution part, and a restoration execution part. The main control circuit has a calibration information storage area for storing calibration information unique to the analysis device, and is configured to perform operation control unique to the analysis device using the calibration information. The sub-control circuit is communicable with the main control circuit and has a backup information storage area for storing the same information as the calibration information in the calibration information storage area. The backup execution part is configured to execute backup for storing information same as the calibration information stored in the calibration information storage area in the backup information storage area.
Abstract: Provided herein are compositions and methods useful for the analysis and authentication of polysaccharide-rich herbs, such as Dendrobium officinale, Radix Astragali, Radix Angelica Sinensis, and related herbal products.
Abstract: A method for analyzing or detecting methimazole (“MTZ”) comprising contacting a sample suspected of containing MTZ with the dendrimer-stabilized silver nanoparticles and performing surface-enhanced Raman scattering (SERS). Graphene-dendrimer-stabilized silver nanoparticles (G-D-Ag).
Type:
Grant
Filed:
March 13, 2018
Date of Patent:
October 18, 2022
Assignee:
King Fahd University of Petroleum and Minerals
Inventors:
Tawfik A. Saleh, Mutasem M. Al-Shalafeh, Abdulaziz A. Al-Saadi
Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
Abstract: The present disclosure relates to a method for detecting a compound, comprising the steps of: contacting a compound with a solid analytical surface (SAS), thereby forming an SAS with an absorbed compound; contacting the SAS with the absorbed compound with a mass tag, wherein the mass tag reacts with the absorbed compound, thereby forming an SAS with a covalently mass-tagged absorbed compound; and detecting the covalently mass-tagged absorbed compound by mass spectrometry. Also disclosed is a device for collecting breath aerosol, comprising a card or an envelope, wherein the card or the envelope comprise a tab, wherein the tab is a SAS.
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
September 27, 2022
Assignee:
Northeastern University
Inventors:
Pushkar Kulkarni, Poguang Wang, Roger W. Giese
Abstract: Disclosed is a highly sensitive assay method and assay kit for HBsAg, which do not require treatment with a strong acid or alkali in the sample pretreatment, and which is less susceptible to influences by the autoantibodies. The assay method for hepatitis B virus s antigen in a sample separated from a living body includes: a pretreatment step of mixing a sample with a pretreatment reagent containing a reducing agent, to reduce hepatitis B virus s antigen; and an immunoassay step of subjecting the pretreated sample to an immunoassay of hepatitis B virus s antigen using at least one antibody or antigen-binding fragment thereof capable of antigen-antibody reaction with a reduced peptide composed of the amino acids at positions 98 to 179 of hepatitis B virus s antigen.
Abstract: An exemplary chromatographic alignment system accesses a target file including data representative of a plurality of chromatographic features detected from a first sample and a reference file including data representative of a plurality of chromatographic features detected from a second sample. The system identifies, based on the target and reference files, a distinct retention time offset value for each chromatographic feature included in a first subset of the plurality of chromatographic features detected from the first sample. The system determines, based on the identified distinct retention time offset values for the chromatographic features included in the first subset and on a machine learning model, a distinct predicted retention time offset value for each chromatographic feature included in a second subset of the plurality of chromatographic features detected from the first sample.
Abstract: This disclosure relates to synthetic ligands for detecting PD-L1 in a sample or subject. The ligand can be labeled with a variety of detectable labels allowing of visualization and quantification. The ligand provides an alternative PD-L1 binding molecule with advantages over current antibody technologies for detecting PD-L1.
Type:
Grant
Filed:
September 27, 2017
Date of Patent:
September 20, 2022
Assignee:
The Curators of the University of Missouri
Abstract: A confirmation ion ratio allowable value calculation unit calculates a confirmation ion ratio allowable value when a target ion and confirmation ions are interchanged based on a preset confirmation ion ratio allowable value, and a peak identification processing unit identifies mass peaks of the target ion and the confirmation ions based on the confirmation ion ratio allowable value. A peak waveform processing unit calculates peak areas of the target ion and the confirmation ions, and a calibration curve creation unit creates calibration curves for quantification based on the target ion and the confirmation ions from a peak area of a target compound included in a standard sample. A quantitative value calculation unit obtains quantitative values while referring to a calibration curve corresponding to a peak area for a target compound included in an unknown sample. A quantitative analysis result display processing unit displays the quantitative values and chromatogram peak waveforms.
Abstract: Methods and systems for highly sensitive detection of methylation changes in DNA samples are provided, particularly in DNA samples obtained from biological fluids such as plasma and urine.
Type:
Grant
Filed:
March 17, 2020
Date of Patent:
September 6, 2022
Assignee:
NUCLEIX LTD.
Inventors:
Danny Frumkin, Adam Wasserstrom, Revital Knirsh, Orna Savin
Abstract: While sample extraction device including a sorbent is coupled to a sample vial containing a sample, a vacuum is drawn through the sample extraction device to evaporate the volatile matrix of the sample and carry volatilized target compounds of the sample to the sorbent. Optionally, once the volatile matrix is evaporated, the sample vial is heated and/or the vacuum level is increased to transfer heavier target compounds to the sorbent. Multiple sampling devices can be extracted in parallel. The sample extraction device can be inserted into a thermal desorption device that directly couples the sample extraction device to a gas chromatograph. In some embodiments, the sample is desorbed and analyzed using gas chromatography or another suitable technique. The techniques disclosed herein are used for analysis of volatile organic compounds and semi-volatile organic compounds in water, food, beverages, soils, and other matrices.
Abstract: A specimen liquid sensor apparatus includes a specimen liquid sensor having an external terminal and a reader on which the specimen liquid sensor can be detachably attached. The reader includes a first portion, a second portion that can be displaced with respect to the first portion. A connection terminal located on an upper surface of the first portion, and an external terminal of the specimen liquid sensor and a connection terminal of the reader are in contact with each other in a closed state in which the specimen liquid sensor is located between an upper surface of the first portion and a lower surface of the second portion.
Abstract: The present invention provides rapid and simple methods of testing on whole blood samples for alerting cancer recurrence and assessing cancer progression relying on determination of the functionality of leucocytes (predominately neutrophils) to exhibit challenge-induced superoxide anion production with quantification by chemiluminescent measurement.
Abstract: Methods for achieving complete sequence coverage of monoclonal antibodies by trypsin digestion and dual-column LC-MS system are provided. The disclosed method improves upon current techniques for standard peptide mapping.
Abstract: A chromatographic data system processing apparatus includes a liquid feeder, a sample injector, a column that separates samples, a detector, a controller that processes a detected result of the detector, and a data processor that examines and sets operations of the liquid feeder, the column and the detector, and a measurement condition. The data processor generates a three-dimensional graph having three axes related to a pressure, a time, and a number of theoretical plates based on data or variables indicating a relationship between the number of theoretical plates and a flow rate, and data or variables indicating a relationship between the pressure and the flow rate. The chromatographic data system processing apparatus can easily obtain a separation condition for obtaining performance from a three-dimensional graph including a pressure drop, a hold-up time and a number of theoretical plates.
Abstract: Provided are a method, an apparatus, and a kit for detecting a neuroblastoma in a subject and/or for monitoring a therapeutic effect on the neuroblastoma, by measuring a urinary tumor marker(s) in a sample from the subject.
Type:
Grant
Filed:
November 5, 2019
Date of Patent:
August 16, 2022
Assignees:
NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, HITACHI, LTD.
Abstract: A method for securing qualitative and quantitative information of a high molecular weight additive in a polymer resin sample is disclosed herein. In some embodiments, the method includes separating a fraction of a polymer resin sample using size exclusion chromatography (SEC), wherein the fraction corresponding to a high molecular weight additive, pyrolyzing the fraction in a pyrolysis-gas chromatography/mass spectrometer (Py-GC/MS) to obtain a mass spectrum of the pyrolyzed fraction; identifying a structure of the high molecular weight additive by comparing m/z values for fragment peaks in the mass spectrum to m/z values for fragment peaks in a mass spectrum of a standard, and determining the amount of the high molecular weight additive in the polymer resin sample, relative to the total weight of the polymer resin sample by comparing a sum of areas of the fragment peaks to a calibration line of the standard.
Type:
Grant
Filed:
October 10, 2019
Date of Patent:
August 9, 2022
Inventors:
Seonyoung Jegal, Byoung Hyoun Kim, Dong Hyun Kim, Yura Lee, Hyun Sik You
Abstract: The present invention provides a method and a kit for determining the risk or rate of an individual of developing diabetes related cardiovascular complications in a subject suffering from either type 1 diabetes mellitus or type 2 diabetes mellitus. The method and the kit comprises: determining the levels of two or more biomarkers purified from a biological sample; wherein said biomarkers are selected from the group comprising lysine advanced glycation end products, arginine advanced glycation end products, and oxidation products; and comparing the determined biomarker levels to standard values, wherein the level of said biomarkers indicate the risk or rate of developing diabetes related cardiovascular disease.